Medtronic plc (MDT)
NYSE: MDT · Real-Time Price · USD
82.35
-0.94 (-1.13%)
At close: Jul 21, 2026, 4:00 PM EDT
82.06
-0.29 (-0.35%)
After-hours: Jul 21, 2026, 7:57 PM EDT
Revenue
Financials in millions USD. Fiscal year is May - April.
Millions USD. Fiscal year is May - Apr.
Fiscal Quarter | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 24, 2026 | Jan '26 Jan 23, 2026 | Oct '25 Oct 24, 2025 | Jul '25 Jul 25, 2025 | Apr '25 Apr 25, 2025 | Jan '25 Jan 24, 2025 | Oct '24 Oct 25, 2024 | Jul '24 Jul 26, 2024 | Apr '24 Apr 26, 2024 | Jan '24 Jan 26, 2024 | Oct '23 Oct 27, 2023 | Jul '23 Jul 28, 2023 | Apr '23 Apr 28, 2023 | Jan '23 Jan 27, 2023 | Oct '22 Oct 28, 2022 | Jul '22 Jul 29, 2022 | Apr '22 Apr 29, 2022 | Jan '22 Jan 28, 2022 | Oct '21 Oct 29, 2021 | Jul '21 Jul 30, 2021 | Apr '21 Apr 30, 2021 | Jan '21 Jan 29, 2021 | Oct '20 Oct 30, 2020 | Jul '20 Jul 31, 2020 |
Cardiac Rhythm & Heart Failure Revenue | 2.11B | |||||||||||||||||||||||
Cardiac Rhythm & Heart Failure Revenue Growth | 21.75% | |||||||||||||||||||||||
Structural Heart & Aortic Revenue | 1.00B | |||||||||||||||||||||||
Structural Heart & Aortic Revenue Growth | 6.14% | |||||||||||||||||||||||
Coronary & Peripheral Vascular Revenue | 685.00M | |||||||||||||||||||||||
Coronary & Peripheral Vascular Revenue Growth | 3.94% | |||||||||||||||||||||||
Cardiovascular Revenue | 3.80B | |||||||||||||||||||||||
Cardiovascular Revenue Growth | 13.82% | |||||||||||||||||||||||
Cranial & Spinal Technologies Revenue | 1.40B | |||||||||||||||||||||||
Cranial & Spinal Technologies Revenue Growth | 4.54% | |||||||||||||||||||||||
Specialty Therapies Revenue | 805.00M | |||||||||||||||||||||||
Specialty Therapies Revenue Growth | 6.06% | |||||||||||||||||||||||
Neuromodulation Revenue | 541.00M | |||||||||||||||||||||||
Neuromodulation Revenue Growth | 4.04% | |||||||||||||||||||||||
Neuroscience Revenue | 2.75B | |||||||||||||||||||||||
Neuroscience Revenue Growth | 5.00% | |||||||||||||||||||||||
Surgical & Endoscopy Revenue | 1.82B | |||||||||||||||||||||||
Surgical & Endoscopy Revenue Growth | 6.49% | |||||||||||||||||||||||
Acute Care & Monitoring Revenue | 568.00M | |||||||||||||||||||||||
Acute Care & Monitoring Revenue Growth | 12.92% | |||||||||||||||||||||||
Medical Surgical Revenue | 2.39B | |||||||||||||||||||||||
Medical Surgical Revenue Growth | 7.96% | |||||||||||||||||||||||
Diabetes Revenue | 837.00M | |||||||||||||||||||||||
Diabetes Revenue Growth | 14.97% | |||||||||||||||||||||||
Other Segment Revenue | 34.00M | |||||||||||||||||||||||
Other Segment Revenue Growth | 9.68% | |||||||||||||||||||||||
Revenue (Other) | - | |||||||||||||||||||||||
Revenue (Total) | 9.81B | |||||||||||||||||||||||
Revenue (Total) Growth | 9.86% |
Revenue by Geography
Financials in millions USD. Fiscal year is May - April.
Millions USD. Fiscal year is May - Apr.
Fiscal Quarter | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 24, 2026 | Jan '26 Jan 23, 2026 | Oct '25 Oct 24, 2025 | Jul '25 Jul 25, 2025 | Apr '25 Apr 25, 2025 | Jan '25 Jan 24, 2025 | Oct '24 Oct 25, 2024 | Jul '24 Jul 26, 2024 | Apr '24 Apr 26, 2024 | Jan '24 Jan 26, 2024 | Oct '23 Oct 27, 2023 | Jul '23 Jul 28, 2023 | Apr '23 Apr 28, 2023 | Jan '23 Jan 27, 2023 | Oct '22 Oct 28, 2022 | Jul '22 Jul 29, 2022 | Apr '22 Apr 29, 2022 | Jan '22 Jan 28, 2022 | Oct '21 Oct 29, 2021 | Jul '21 Jul 30, 2021 | Apr '21 Apr 30, 2021 | Jan '21 Jan 29, 2021 | Oct '20 Oct 30, 2020 | Jul '20 Jul 31, 2020 |
U.S. Revenue | 4.87B | |||||||||||||||||||||||
U.S. Revenue Growth | 7.10% | |||||||||||||||||||||||
Total International Revenue | 4.94B | |||||||||||||||||||||||
Total International Revenue Growth | 12.74% | |||||||||||||||||||||||
Revenue (Other) | -1.00M | |||||||||||||||||||||||
Revenue (Total) | 9.81B | |||||||||||||||||||||||
Revenue (Total) Growth | 9.86% |
EBIT
Financials in millions USD. Fiscal year is May - April.
Millions USD. Fiscal year is May - Apr.
Fiscal Quarter | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 24, 2026 | Jan '26 Jan 23, 2026 | Oct '25 Oct 24, 2025 | Jul '25 Jul 25, 2025 | Apr '25 Apr 25, 2025 | Jan '25 Jan 24, 2025 | Oct '24 Oct 25, 2024 | Jul '24 Jul 26, 2024 | Apr '24 Apr 26, 2024 | Jan '24 Jan 26, 2024 | Oct '23 Oct 27, 2023 | Jul '23 Jul 28, 2023 | Apr '23 Apr 28, 2023 | Jan '23 Jan 27, 2023 | Oct '22 Oct 28, 2022 | Jul '22 Jul 29, 2022 | Apr '22 Apr 29, 2022 | Jan '22 Jan 28, 2022 | Oct '21 Oct 29, 2021 | Jul '21 Jul 30, 2021 | Apr '21 Apr 30, 2021 | Jan '21 Jan 29, 2021 | Oct '20 Oct 30, 2020 | Jul '20 Jul 31, 2020 |
Cardiovascular Operating Profit | 1.07B | |||||||||||||||||||||||
Cardiovascular Operating Profit Growth | 11.83% | |||||||||||||||||||||||
Neuroscience Operating Profit | 880.00M | |||||||||||||||||||||||
Neuroscience Operating Profit Growth | 2.68% | |||||||||||||||||||||||
Medical Surgical Operating Profit | 604.00M | |||||||||||||||||||||||
Medical Surgical Operating Profit Growth | 5.04% | |||||||||||||||||||||||
Operating Income (Other) | -679.00M | |||||||||||||||||||||||
Operating Income (Total) | 1.87B | |||||||||||||||||||||||
Operating Income (Total) Growth | 30.43% |
Key Performance Indicators
Financials in millions USD. Fiscal year is May - April.
Millions USD. Fiscal year is May - Apr.
Fiscal Quarter | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 24, 2026 | Jan '26 Jan 23, 2026 | Oct '25 Oct 24, 2025 | Jul '25 Jul 25, 2025 | Apr '25 Apr 25, 2025 | Jan '25 Jan 24, 2025 | Oct '24 Oct 25, 2024 | Jul '24 Jul 26, 2024 | Apr '24 Apr 26, 2024 | Jan '24 Jan 26, 2024 | Oct '23 Oct 27, 2023 | Jul '23 Jul 28, 2023 | Apr '23 Apr 28, 2023 | Jan '23 Jan 27, 2023 | Oct '22 Oct 28, 2022 | Jul '22 Jul 29, 2022 | Apr '22 Apr 29, 2022 | Jan '22 Jan 28, 2022 | Oct '21 Oct 29, 2021 | Jul '21 Jul 30, 2021 | Apr '21 Apr 30, 2021 | Jan '21 Jan 29, 2021 | Oct '20 Oct 30, 2020 | Jul '20 Jul 31, 2020 |
Cardiovascular Organic Revenue Growth | 10.10% | |||||||||||||||||||||||
Neuroscience Organic Revenue Growth | 3.00% | |||||||||||||||||||||||
Medical Surgical Organic Revenue Growth | 5.10% | |||||||||||||||||||||||
Diabetes Organic Revenue Growth | 8.10% | |||||||||||||||||||||||
Total Organic Revenue Growth | 6.60% |